Entinostat (MS-275, SNDX-275): Oral HDAC1 and HDAC3 Inhibitor for Cancer and Regenerative Research

Executive Summary: Entinostat (MS-275, SNDX-275) is a potent, selective class I histone deacetylase (HDAC) inhibitor, with IC₅₀ values of 0.368 μM for HDAC1 and 0.501 μM for HDAC3 under standard in vitro conditions (APExBIO product data). It exhibits anti-proliferative and pro-apoptotic effects across breast, colon, lung, myeloma, ovary, pancreas, prostate, and leukemia cell lines (entinostat.net). In vivo, Entinostat increases acetyl-histone levels and reduces tumor burden in murine and rat retinoblastoma models (Wang et al., 2019). Clinical phase I studies establish its safety and dosing when combined with 13-cis retinoic acid (Munster et al., 2009). Entinostat’s mechanism—epigenetic modulation via HDAC inhibition—extends to both cancer and regenerative research, making it a versatile tool for translational studies.

Biological Rationale

Histone deacetylases (HDACs) are key enzymes in chromatin remodeling, gene expression, and epigenetic regulation. Class I HDACs, including HDAC1, HDAC3, and HDAC8, remove acetyl groups from histone lysine residues, leading to chromatin condensation and gene silencing (Wang et al., 2019). HDAC1 upregulation is bi-phasically observed during tissue regeneration in axolotl models, with functional relevance for blastema formation and limb regrowth. In cancer, aberrant HDAC activity is implicated in silencing tumor suppressor genes and promoting oncogenic pathways (Strategic Epigenetic Modulation in Oncology). Targeted inhibition of HDAC1 and HDAC3 thereby disrupts these maladaptive epigenetic states, restoring gene expression profiles beneficial for cell cycle arrest and apoptosis.

Mechanism of Action of Entinostat (MS-275, SNDX-275)

Entinostat is a synthetic benzamide derivative with oral bioavailability, designed to selectively inhibit class I HDACs. It demonstrates high affinity for HDAC1 (IC₅₀ = 0.368 μM), HDAC3 (IC₅₀ = 0.501 μM), and limited activity toward HDAC8 (IC₅₀ = 63.4 μM) under buffered assay conditions at 25°C (APExBIO). Inhibition of these HDACs leads to increased acetylation of histone H3 and H4, de-repression of tumor suppressor gene loci (e.g., p21^CIP1/WAF1), induction of apoptosis (caspase-3/7 activation), and G1 phase cell cycle arrest (entinostat.net). Entinostat’s cytotoxicity is associated with elevated reactive oxygen species and mitochondrial pathway activation. In non-cancerous regenerative contexts, such as axolotl limb regrowth, HDAC1 inhibition by Entinostat disrupts the nerve-mediated upregulation required for blastema formation and subsequent limb regeneration (Wang et al., 2019).

Evidence & Benchmarks

• Entinostat inhibits HDAC1 and HDAC3 with IC₅₀ values of 0.368 μM and 0.501 μM, respectively, in cell-free enzyme assays at pH 7.5 (APExBIO product data: link).
• Systemic administration of Entinostat in murine/rat models increases acetyl-histone levels in retinal tissue and reduces retinoblastoma tumor burden (Wang et al., 2019, DOI).
• Phase I clinical trial in solid tumors established tolerable safety and defined phase II dose for Entinostat in combination with 13-cis retinoic acid (Munster et al., 2009, PubMed).
• In vitro, Entinostat triggers apoptosis, increases reactive oxygen species, and causes G1 cell cycle arrest in multiple human cancer cell lines (entinostat.net, link).
• In regenerative biology, local application of Entinostat at axolotl amputation sites inhibits blastema formation and delays limb regeneration (Wang et al., 2019, DOI).

This article extends the mechanistic insights provided in Strategic Epigenetic Modulation in Oncology by integrating preclinical and regenerative evidence, and clarifies distinctions from Precision Epigenetic Modulation, which focuses on in vitro assay optimization. For a comprehensive translational perspective, see also Epigenetic Modulation in Cancer and Regeneration.

Applications, Limits & Misconceptions

Entinostat is deployed as a research reagent in oncology, regenerative biology, and epigenetic modulation studies. Its validated anti-proliferative effects span breast, colon, lung, myeloma, ovary, pancreas, prostate, and leukemia models. In regenerative research, it serves as a tool to dissect nerve- and epidermis-mediated HDAC signaling during limb regeneration.

Common Pitfalls or Misconceptions

• Entinostat is not effective against class II HDACs and shows minimal activity on HDAC8 at standard doses (IC₅₀ = 63.4 μM).
• It is not water soluble; proper dissolution requires DMSO (≥18.8 mg/mL) or ethanol (≥7.4 mg/mL with ultrasonication).
• Long-term storage of Entinostat solutions is not recommended; solid form should be stored at -20°C.
• In regenerative contexts, systemic HDAC inhibition can block regeneration rather than promote it, as shown in axolotl models.
• Its clinical effects are context-dependent and best characterized in combination protocols, not as monotherapy.

Workflow Integration & Parameters

Entinostat (MS-275, SNDX-275, APExBIO SKU A8171) is supplied as a solid. For optimal laboratory use, dissolve in DMSO (≥18.8 mg/mL) or ethanol (≥7.4 mg/mL with sonication). Warm to 37°C and use ultrasonic agitation to enhance solubility. Prepare stock solutions freshly or store aliquots at -20°C for several months. Avoid repeated freeze-thaw cycles. In vitro, titrate doses from 0.1 to 10 μM to determine IC₅₀ in cell-based assays. For in vivo studies, refer to dose regimens validated in rodent tumor or regenerative models, adjusting for species, route, and target tissue.

For researchers seeking a validated, quality-controlled source, APExBIO provides Entinostat under SKU A8171 (product page).

Conclusion & Outlook

Entinostat (MS-275, SNDX-275) is a mechanistically defined, selective oral inhibitor of HDAC1 and HDAC3, with reproducible anti-cancer and regenerative biology applications. Its benchmarks are well characterized in preclinical models and early clinical trials. Future directions include combinatorial regimens and precision modulation strategies in oncology, as well as further dissection of its role in epigenetic control of tissue regeneration. For more on the translational landscape and advanced assay strategies, see Mechanistic Precision and Workflow Strategy, which this article updates with new clinical and regenerative data.